TY  - JOUR 
AU  - Valladares Ayerbes, Manuel
PY  - 2012
SN  - 1083-7159
UR  - http://hdl.handle.net/20.500.11940/7531
LA  - eng
TI  - First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study
DO  - 10.1634/theoncologist.2011-0249
T2  - ONCOLOGIST
VL  - 17
ER  -